Citations

Clear

941 citation(s) found for "Tefferi, A".

A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia
Steensma, David P. , Pardanani, Animesh , Li, Chin‐Yang, Elliott, Michelle A. , Wiseman, Gregory A., Gray, Leigh A., Schroeder, Georgene, Reeder, Terra L. , Zeldis, Jerome B. , Tefferi, Ayalew , Mesa, Ruben A. , Li, Chin‐Yang, Kaufmann, Scott H. , Steensma, David P

Mayo Clinic

Blood | March 17, 2003 | Volume: 101 | Issue: 7 | Pages: 2534-2541

10.1182/blood-2002-09-2928 | PMID 12517815 Get It

Single-agent thalidomide (THAL) at “conventional” doses (> 100 mg/d) has been evaluated in myelofibrosis with myeloid metaplasia (MMM) based on its antiangiogenic properties and the prominent neoangiogenesis that occurs in MMM. THAL monotherapy at such doses produces approximately a 20% response rate in anemia but is poorly tolerated (an adverse dropout rate of > 50% in 3 months). To improve efficacy and tolerability, we prospectively treated 21 symptomatic patients (hemoglobin level < 10 g/dL or symptomatic splenomegaly) with MMM with low-dose THAL (50 mg/d) along with a 3-month oral prednisone (PRED) taper (beginning at 0.5 mg/kg/d). THAL-PRED was well tolerated in all enrolled patients, with 20 patients (95%) able to complete 3 months of treatment. An objective clinical response was demonstrated in 13 (62%) patients, all improvements in anemia. Among 10 patients who were dependent on erythrocyte transfusions, 7 (70%) improved and 4 (40%) became transfusion independent. Among 8 patients with thrombocytopenia (platelet count < 100 × 109/L), 6 (75%) experienced a 50% or higher increase in their platelet count. In 4 of 21 patients (19%), spleen size decreased by more than 50%. Responses observed were mostly durable after discontinuation of the PRED. The dose of THAL in this study (50 mg/d) was better tolerated than the higher doses used in previous studies. Adverse events associated with corticosteroid therapy were mild and transient. Clinical responses did not correlate with improvements in either intramedullary fibrosis or angiogenesis. THAL-PRED is well tolerated and preliminarily appears to be a promising drug regimen for treating cytopenias in patients with MMM.
Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome
Steensma, David P. , Dispenzieri, Angela , Moore, S. Breanndan, Schroeder, Georgene, Tefferi, Ayalew , Dispenzieri, Angela , Steensma, David P

Mayo Clinic

Blood | February 27, 2003 | Volume: 101 | Issue: 6 | Pages: 2156-2158

10.1182/blood-2002-09-2867 | PMID 12411290 Get It

Antithymocyte globulin (ATG) has recently been popularized as an effective treatment in myelodysplastic syndrome (MDS). We treated 8 anemic MDS patients (refractory anemia [RA] and refractory anemia with excess blasts [RAEB-1]) with ATG (40 mg/kg/d for 4 days) and prednisone in a phase 2 trial. The study was stopped early according to a preset termination rule because of lack of efficacy. There were no salutary responses. Toxicities included serum sickness (in all patients), transient neutropenia and thrombocytopenia, diarrhea, vomiting, and syncope with a generalized seizure. At least 3 patients had the HLA-DR15 (DR2) allele. We conclude that the risk-benefit ratio of ATG in an unselected population of MDS patients may be unfavorable, and more work is needed to define the subset of patients who will respond to ATG before its widespread use can be recommended.
Both B and T lymphocytes may be clonally involved in myelofibrosis with myeloid metaplasia
Reeder, Terra L. , Bailey, Richard J., Dewald, Gordon W., Tefferi, Ayalew

Mayo Clinic

Blood | February 12, 2003 | Volume: 101 | Issue: 5 | Pages: 1981-1983

10.1182/blood-2002-07-2341 | PMID 12406879 Get It

A combination of magnetic cell sorting (MACS) and fluorescent in situ hybridization (FISH) techniques was used to detect clonal cytogenetic markers in different myeloid and lymphoid cell types of the peripheral blood from 4 patients with myelofibrosis with myeloid metaplasia (MMM) that was associated with either a 13q− or a 20q− karyotypic abnormality. Interphase cytogenetics studies demonstrated abnormal clonal FISH signal patterns in neutrophil, myeloid, erythroid, megakaryocyte, and B- and T-cell preparations in 3 of the 4 patients. In one patient, FISH results were within normal limits in T cells and slightly abnormal in B cells. In general, the percentage of abnormal nuclei was variable in both lymphocyte populations but always higher in B lymphocytes compared with T lymphocytes. The current study provides direct evidence for the clonal involvement of both B and T lymphocytes in MMM. A larger study is needed to clarify the relevance of the observed interpatient heterogeneity in clonal constitution.
Lymphomas in Patients With Connective Tissue Disease
Menke, David M. , Griesser, Henrik, Moder, Kevin G., Tefferi, Ayalew , Luthra, Harvinder S., Cohen, Marc D., Colón‐Otero, Gerardo , Lloyd, Ricardo V.

Mayo Clinic

American Journal of Clinical Pathology | January 8, 2003 | Volume: 113 | Issue: 2 | Pages: 212-218

10.1309/vf28-e64g-1dnd-lf94 | PMID 10664623 Get It

Outcome of Diffuse Alveolar Hemorrhage in Hematopoietic Stem Cell Transplant Recipients
Afessa, Bekele, Tefferi, Ayalew , Litzow, Mark R. , Peters, Steve G.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | November 15, 2002 | Volume: 166 | Issue: 10 | Pages: 1364-1368

10.1164/rccm.200208-792oc | PMID 12406834 Get It

Abstract Previous studies have reported mortality rates of about 80% in hematopoietic stem cell transplant recipients with diffuse alveolar hemorrhage. This retrospective study describes the clinical course of 48 such patients: mean age 47.7 years, 52% autologous transplant and 67% peripheral stem cell source. The hemorrhage occurred within one month of transplant in 28 patients. Symptoms included dyspnea in 92%, fever in 67%, cough in 56%, and hemoptysis in 15%. Intensive care unit admission was required in 85% and mechanical ventilation in 77%. Most of the patients were treated with intravenous methylprednisolone 1 g daily for 3 days and then tapered off after a median of 22 days. The hospital mortality was 48%. The cause of death was respiratory failure in 15 of the 23 deaths. Mortality was 28% in autologous compared with 70% in allogeneic transplant recipients (p = 0.0040). The mortality rate of patients whose hemorrhage occurred within the first 30 days of transplant was 32% compared with 70% of those with late hemorrhage (p = 0.0096). This study shows that survival rate of hematopoietic stem cell transplant recipients with diffuse alveolar hemorrhage is better than previously reported, and that early onset and autologous transplant are favorable prognostic indicators.
Selective serotonin reuptake inhibitors are effective in the treatment of polycythemia vera–associated pruritus
Tefferi, Ayalew , Fonseca, Rafaël , Fonseca, Rafael

Mayo Clinic

Blood | October 11, 2002 | Volume: 99 | Issue: 7 | Pages: 2627-2627

10.1182/blood.v99.7.2627 | PMID 11926187 Get It

Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia
Tefferi, Ayalew , Gray, Leigh A., Steensma, David P. , Camoriano, John , Elliott, Michelle A. , Pardanani, Animesh , Ansell, Stephen M. , Call, Timothy G. , Colón‐Otero, Gerardo , Schroeder, Georgene, Hanson, Curtis A. , Dewald, Gordon W., Mesa, Ruben A. , Kaufmann, Scott H. , Steensma, David P

Mayo Clinic

Blood | October 11, 2002 | Volume: 99 | Issue: 10 | Pages: 3854-3856

10.1182/blood-2001-12-0154 | PMID 11986248 Get It

In a phase 2 study, 23 patients with myelofibrosis with myeloid metaplasia were treated with imatinib mesylate at a constant dose of 400 mg/d. Treatment was held in 16 patients (70%), after 1 to 12 weeks, because of side effects (neutropenia, 6 patients; musculoskeletal pain, 5 patients; thrombocytosis, 4 patients; edema, 3 patients; diarrhea and hyperbilirubinemia, 1 patient). Including patients in whom retreatment at a reduced dose was possible, 11 patients (48%) were able to continue treatment beyond 3 months. None of the patients experienced a response in anemia, and only 2 had partial responses in splenomegaly. A greater than 50% increase in platelet count was documented in 11 (48%) patients, but not in those with baseline platelet counts of less than 100 × 109/L. In vitro, imatinib mesylate caused variable degrees of growth suppression of myeloid and erythroid progenitors that unfortunately did not translate into clinical benefit.
Etanercept, a soluble tumor necrosis factor receptor, palliates constitutional symptoms in patients with myelofibrosis with myeloid metaplasia: results of a pilot study
Steensma, David P. , Li, Chin‐Yang, Gray, Leigh A., Tefferi, Ayalew , Mesa, Ruben A. , Li, Chin‐Yang, Steensma, David P

Mayo Clinic

Blood | October 1, 2002 | Volume: 99 | Issue: 6 | Pages: 2252-2254

10.1182/blood.v99.6.2252 | PMID 11877307 Get It

AbstractPatients with myelofibrosis with myeloid metaplasia (MMM) often experience debilitating constitutional symptoms such as drenching night sweats, profound fatigue, unexplained fevers, and unintentional weight loss. Tumor necrosis factor (TNF) contributes to organ fibrosis and hypercatabolic symptoms in a variety of disease states. We conducted an open-label pilot study of etanercept, a soluble TNF receptor, administered at a dose of 25 mg subcutaneously twice weekly for up to 24 weeks in 22 patients with MMM. Of 20 evaluable patients, 12 (60%) experienced an improvement in constitutional symptoms, and 4 (20%) had an objective response (improvement in peripheral cytopenias or spleen size). The degree of marrow fibrosis was unchanged, and only minor changes in overall marrow cellularity were observed. Toxicity was mild, with injection site reactions (20%) and minor infections (10%) as the most common side effects. One patient developed reversible pancytopenia. Etanercept may be useful for palliation of constitutional symptoms in MMM.
Diagnostic and prognostic value of bone marrow angiogenesis and megakaryocyte c-Mpl expression in essential thrombocythemia
Hanson, Curtis A. , Li, Chin‐Yang, Yoon, Soo‐Young , Rajkumar, S. Vincent , Schroeder, Georgene, Tefferi, Ayalew , Mesa, Ruben A. , Li, Chin‐Yang, Rajkumar, S Vincent

Mayo Clinic

Blood | October 1, 2002 | Volume: 99 | Issue: 11 | Pages: 4131-4137

10.1182/blood.v99.11.4131 | PMID 12010817 Get It

The lack of diagnostic certainty in some patients makes it difficult to distinguish between primary and secondary forms of thrombocytosis. To augment current diagnostic studies for thrombocytosis, we retrospectively evaluated clinical records and bone marrow trephine specimens of 183 patients with thrombocytosis—164 with essential thrombocythemia (ET), 19 with reactive thrombocytosis (RT)—for bone marrow angiogenesis, bone marrow megakaryocyte c-Mpl staining, and morphologic evidence of megakaryocyte proliferation. Angiogenesis was increased in patients with ET compared with healthy controls (P &lt; .0001) and patients with RT (P = .006). In addition, an increase in angiogenesis was associated with certain disease features such as splenomegaly (P = .004) and reticulin fibrosis (P = .005). Decreased megakaryocyte c-Mpl staining was observed in a heterogeneous pattern in ET compared with healthy controls (P &lt; .0001) and RT (P &lt; .0001). Histologic stratifying criteria incorporating increased angiogenesis, decreased megakaryocyte c-Mpl expression, and marked megakaryocyte proliferation in the bone marrow was highly sensitive (97%) and specific (95%) for distinguishing ET from RT (P &lt; .0001). However, with the current duration of follow-up available on the patients, none of the histologic features evaluated have yet demonstrated prognostic value for subsequent clinical course, vascular events, or survival.
Diffuse Alveolar Hemorrhage in Hematopoietic Stem Cell Transplant Recipients
Afessa, Bekele, Tefferi, Ayalew , Litzow, Mark R. , Krowka, Michael J. , Wylam, Mark E. , Peters, Steve G.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | August 30, 2002 | Volume: 166 | Issue: 5 | Pages: 641-645

10.1164/rccm.200112-141cc | PMID 12204858 Get It